Detail akcie OraSure Tech online

Business Summary: OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.
Financial Summary: BRIEF: For the six months ended 30 June 2026, OraSure Technologies Inc revenues decreased 4% to $58.6M. Net loss decreased 55% to $16.1M. Revenues reflect Net product and service revenues -Molecular Products segment decrease of 42% to $4.9M, Net product and service revenues -Molecular Services segment decrease of 96% to $19K, Africa (Region) segment decrease of 11% to $13.6M, United States segment decrease of 3% to $38.9M.